- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- Ovid from 2009, Gale, CSA, Proquest, and Futuremedicine
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials.
Evaluation of: Lasky JL 3rd, Panosyan EH, Plant A et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 33, 2047-2056 (2013). Immunotherapy for children and adults with high-grade glioma (HGG) i...
A retrospective survey of the quality of reports and their correlates among randomized controlled trials of immunotherapy for Guillain-Barré...
A total of 19 RCTs were included in the full text. The median OQS was 7.0, with a range of 1-10. However, the quality of reporting in items of 'flow chart' and 'ancillary analyses' was poor with a positive rate of less than 40%. The median MIS was 0 with a range of 0-2. Twelve (63.2%) did not report...
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Conventional imaging is suboptimal at evaluating disease status in renal cell carcinoma (RCC) because of poor sensitivity. Furthermore, there is an unmet need for the treatment of metastatic RCC, both in terms of improvement of progression-free survival and limitation of toxicity. For this reason, r...
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF.
Immunotherapeutic applications of IL-18.
To become active and extracellularly released, IL-18 needs post-translational processing by the cytoplasmic enzyme caspase-1, which has high sequence homology with apoptotic cell death-associated enzymes in Caenorhabditis elegans. Furthermore, the receptor for IL-18 shares the signal transduction pa...
Clinical trial shows sublingual immunotherapy to be effective for treatment of children with grass pollen allergy.
Is there a role for cytokine-induced killer cells in cancer immunotherapy?
The case for HER2/neu as a therapeutic target for gynecologic malignancies.
Evaluation of: Guzzo F, Bellone S, Buza N et al. HER2/neu as a potential target for immunotherapy in gynecological carcinosarcomas. Int. J. Gynecol. Pathol. 31, 211-221 (2012). Trastuzumab (Herceptin(®)) is a human monoclonal antibody that is US FDA-approved for the treatment of HER2/neu-overexpress...
Sinomenine can prolong high-risk corneal graft survival in a rat model.
To study the role of sinomenine (SIN) in prolonging high-risk corneal graft survival in rats.
Conference scene: progress with promising human antibodies.
Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of...